These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 18477557)

  • 21. Management of rosiglitazone-induced edema: two case reports and a review of the literature.
    Wang F; Aleksunes LM; Reagan LA; Vergara CM
    Diabetes Technol Ther; 2002; 4(4):505-14. PubMed ID: 12396745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?
    Patel C; Wyne KL; McGuire DK
    Diab Vasc Dis Res; 2005 May; 2(2):61-6. PubMed ID: 16305060
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluid retention and vascular effects of rosiglitazone in obese, insulin-resistant, nondiabetic subjects.
    Rennings AJ; Smits P; Stewart MW; Tack CJ
    Diabetes Care; 2006 Mar; 29(3):581-7. PubMed ID: 16505510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial.
    Komajda M; McMurray JJ; Beck-Nielsen H; Gomis R; Hanefeld M; Pocock SJ; Curtis PS; Jones NP; Home PD
    Eur Heart J; 2010 Apr; 31(7):824-31. PubMed ID: 20118174
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The rise and fall of rosiglitazone: reply.
    Slaoui M
    Eur Heart J; 2010 May; 31(10):1282-4. PubMed ID: 20499440
    [No Abstract]   [Full Text] [Related]  

  • 26. Rosiglitazone and cardiotoxicity--weighing the evidence.
    Nathan DM
    N Engl J Med; 2007 Jul; 357(1):64-6. PubMed ID: 17551161
    [No Abstract]   [Full Text] [Related]  

  • 27. Thiazolidinedione associated volume overload and pulmonary hypertension.
    Michaelson J
    Ther Adv Cardiovasc Dis; 2008 Dec; 2(6):435-8. PubMed ID: 19124440
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rosiglitazone and heart failure: the controversy and clinical implications.
    Virk IS; Ruby RS; Tepper D
    Congest Heart Fail; 2007; 13(5):293-5. PubMed ID: 17917497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effect of insulin plus rosiglitazone or metformin on serum N-terminal pro-brain natriuretic peptide in type 2 diabetes mellitus: a randomized-controlled study].
    Hu M; Tian H; Zhou X; Wu W; Luo Y; Zhang H
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2008 Jun; 25(3):682-5. PubMed ID: 18693456
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.
    Graham DJ; Ouellet-Hellstrom R; MaCurdy TE; Ali F; Sholley C; Worrall C; Kelman JA
    JAMA; 2010 Jul; 304(4):411-8. PubMed ID: 20584880
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined thiazolidinedione-insulin therapy: should we be concerned about safety?
    Scheen AJ
    Drug Saf; 2004; 27(12):841-56. PubMed ID: 15366973
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
    Wang CC; Chen WL; Kao TW; Chang YW; Loh CH; Chou CC
    Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Severe hypo-alpha-lipoproteinemia during treatment with rosiglitazone.
    Sarker A; Semple RK; Dinneen SF; O'Rahilly S; Martin SC
    Diabetes Care; 2004 Nov; 27(11):2577-80. PubMed ID: 15504988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rosiglitazone and pulmonary oedema: an acute dose-dependent effect on human endothelial cell permeability.
    Idris I; Gray S; Donnelly R
    Diabetologia; 2003 Feb; 46(2):288-90. PubMed ID: 12627329
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The rosiglitazone decision process at FDA and EMA. What should we learn?
    Pouwels KB; van Grootheest K
    Int J Risk Saf Med; 2012; 24(2):73-80. PubMed ID: 22751189
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Glitazones and congestive heart failure: update on PROactive, ADOPT, DREAM and RECORD clinical trials].
    De Flines J; Scheen AJ
    Rev Med Suisse; 2007 Aug; 3(122):1876, 1878-83. PubMed ID: 17896661
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thiazolidinediones and fluid retention.
    Kiryluk K; Isom R
    Kidney Int; 2007 Sep; 72(6):762-8. PubMed ID: 17637710
    [No Abstract]   [Full Text] [Related]  

  • 39. Thiazolidinediones and congestive heart failure: a judicious balance of risks and benefits.
    Patel RR
    Cardiol Rev; 2009; 17(3):132-5. PubMed ID: 19384087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rosiglitazone, but not pioglitazone, improves myocardial systolic function in type 2 diabetic patients: a tissue Doppler study.
    Pala S; Esen O; Akçakoyun M; Kahveci G; Kargin R; Tigen K; Karaahmet T; Açar G; Esen AM; Kirma C
    Echocardiography; 2010 May; 27(5):512-8. PubMed ID: 20412274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.